nodes	percent_of_prediction	percent_of_DWPC	metapath
Bupranolol—Gemfibrozil—SLCO1B1—breast cancer	0.0511	0.373	CrCbGaD
Bupranolol—Terbutaline—BCHE—breast cancer	0.0155	0.113	CrCbGaD
Bupranolol—Clenbuterol—TNF—breast cancer	0.012	0.0879	CrCbGaD
Bupranolol—Gemfibrozil—CYP3A4—breast cancer	0.0111	0.0812	CrCbGaD
Bupranolol—Clenbuterol—CYP1A1—breast cancer	0.00915	0.0668	CrCbGaD
Bupranolol—Timolol—CYP2D6—breast cancer	0.00889	0.0649	CrCbGaD
Bupranolol—Carteolol—CYP2D6—breast cancer	0.00792	0.0578	CrCbGaD
Bupranolol—Timolol—ABCB1—breast cancer	0.00634	0.0463	CrCbGaD
Bupranolol—Salbutamol—CYP3A4—breast cancer	0.00543	0.0396	CrCbGaD
Bupranolol—Nadolol—ABCB1—breast cancer	0.00504	0.0368	CrCbGaD
Bupranolol—Pindolol—CYP2D6—breast cancer	0.00444	0.0324	CrCbGaD
Bupranolol—ADRB2—Signaling Pathways—CXCR4—breast cancer	0.000299	0.000347	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—NOTCH1—breast cancer	0.000297	0.000344	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—TCF7L2—breast cancer	0.000295	0.000342	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—PAK1—breast cancer	0.000294	0.00034	CbGpPWpGaD
Bupranolol—ADRB1—GPCR downstream signaling—AKT2—breast cancer	0.000294	0.00034	CbGpPWpGaD
Bupranolol—ADRB1—Signaling by GPCR—PIK3CG—breast cancer	0.000291	0.000338	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—APC—breast cancer	0.00029	0.000336	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—PIK3CG—breast cancer	0.00029	0.000336	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—KIT—breast cancer	0.00029	0.000336	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—TCF7L2—breast cancer	0.000288	0.000334	CbGpPWpGaD
Bupranolol—ADRB2—GPCR downstream signaling—AKT2—breast cancer	0.000287	0.000333	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—EGF—breast cancer	0.000287	0.000332	CbGpPWpGaD
Bupranolol—ADRB2—Signaling by GPCR—PIK3CG—breast cancer	0.000285	0.00033	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—NOTCH2—breast cancer	0.000284	0.000329	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—HSP90AA1—breast cancer	0.000284	0.000329	CbGpPWpGaD
Bupranolol—ADRB1—GPCR downstream signaling—PIK3CD—breast cancer	0.000282	0.000327	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—NOTCH2—breast cancer	0.000278	0.000322	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—HSP90AA1—breast cancer	0.000278	0.000322	CbGpPWpGaD
Bupranolol—ADRB3—Signaling by GPCR—MAPK3—breast cancer	0.000278	0.000322	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—AGTR1—breast cancer	0.000277	0.000321	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—PRL—breast cancer	0.000277	0.000321	CbGpPWpGaD
Bupranolol—ADRB2—GPCR downstream signaling—PIK3CD—breast cancer	0.000276	0.00032	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—STK11—breast cancer	0.000273	0.000316	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—ADAM10—breast cancer	0.000273	0.000316	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—BRAF—breast cancer	0.000273	0.000316	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—AGTR1—breast cancer	0.000271	0.000314	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—PRL—breast cancer	0.000271	0.000314	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—PLG—breast cancer	0.00027	0.000312	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—STK11—breast cancer	0.000267	0.000309	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—ADAM10—breast cancer	0.000267	0.000309	CbGpPWpGaD
Bupranolol—ADRB1—Signaling by GPCR—AKT2—breast cancer	0.000267	0.000309	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—IGF1—breast cancer	0.000266	0.000308	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—AKT2—breast cancer	0.000265	0.000307	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—FGF10—breast cancer	0.000265	0.000307	CbGpPWpGaD
Bupranolol—ADRB3—Signaling by GPCR—EGFR—breast cancer	0.000264	0.000306	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—PLG—breast cancer	0.000264	0.000306	CbGpPWpGaD
Bupranolol—ADRB2—Signaling by GPCR—AKT2—breast cancer	0.000261	0.000302	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—FGF10—breast cancer	0.000259	0.000301	CbGpPWpGaD
Bupranolol—ADRB1—Signaling by GPCR—PIK3CD—breast cancer	0.000256	0.000297	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—PDGFA—breast cancer	0.000256	0.000297	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—PIK3CD—breast cancer	0.000255	0.000295	CbGpPWpGaD
Bupranolol—ADRB3—GPCR downstream signaling—PIK3CA—breast cancer	0.000253	0.000293	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—TGFBR2—breast cancer	0.000252	0.000292	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—SERPINE1—breast cancer	0.000252	0.000292	CbGpPWpGaD
Bupranolol—ADRB2—Signaling by GPCR—PIK3CD—breast cancer	0.000251	0.00029	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—PDGFA—breast cancer	0.00025	0.00029	CbGpPWpGaD
Bupranolol—ADRB3—Signaling by GPCR—KRAS—breast cancer	0.00025	0.000289	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—ITPR1—breast cancer	0.000248	0.000288	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—TGFBR2—breast cancer	0.000247	0.000286	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—ERBB4—breast cancer	0.000247	0.000286	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—MMP3—breast cancer	0.000247	0.000286	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—STAT5A—breast cancer	0.000247	0.000286	CbGpPWpGaD
Bupranolol—ADRB1—GPCR downstream signaling—PIK3CB—breast cancer	0.000246	0.000285	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—ITPR1—breast cancer	0.000243	0.000281	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—ERBB4—breast cancer	0.000241	0.000279	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—MMP3—breast cancer	0.000241	0.000279	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—STAT5A—breast cancer	0.000241	0.000279	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—NOS3—breast cancer	0.000241	0.000279	CbGpPWpGaD
Bupranolol—ADRB2—GPCR downstream signaling—PIK3CB—breast cancer	0.00024	0.000279	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—SMAD4—breast cancer	0.000239	0.000277	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—IGF1R—breast cancer	0.000237	0.000275	CbGpPWpGaD
Bupranolol—ADRB1—GPCR downstream signaling—CXCL8—breast cancer	0.000236	0.000274	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—SMAD4—breast cancer	0.000234	0.000271	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—HES1—breast cancer	0.000233	0.00027	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—IGF1R—breast cancer	0.000232	0.000269	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—PLA2G4A—breast cancer	0.000232	0.000269	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—NCOR1—breast cancer	0.000232	0.000269	CbGpPWpGaD
Bupranolol—ADRB2—GPCR downstream signaling—CXCL8—breast cancer	0.000231	0.000268	CbGpPWpGaD
Bupranolol—ADRB3—Signaling by GPCR—PIK3CA—breast cancer	0.000229	0.000266	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—CSF2—breast cancer	0.000229	0.000266	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—FGF1—breast cancer	0.000229	0.000266	CbGpPWpGaD
Bupranolol—ADRB1—Signaling by GPCR—RAF1—breast cancer	0.000229	0.000265	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—MDM2—breast cancer	0.000228	0.000265	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—HES1—breast cancer	0.000228	0.000264	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—RAF1—breast cancer	0.000228	0.000264	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—NRG1—breast cancer	0.000228	0.000264	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—NCOR1—breast cancer	0.000227	0.000263	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—PLA2G4A—breast cancer	0.000227	0.000263	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—RELA—breast cancer	0.000227	0.000263	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—H2AFX—breast cancer	0.000226	0.000262	CbGpPWpGaD
Bupranolol—ADRB1—GPCR downstream signaling—IL2—breast cancer	0.000226	0.000262	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—ERBB2—breast cancer	0.000225	0.000261	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—E2F1—breast cancer	0.000224	0.00026	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—CSF2—breast cancer	0.000224	0.00026	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—FGF1—breast cancer	0.000224	0.00026	CbGpPWpGaD
Bupranolol—ADRB2—Signaling by GPCR—RAF1—breast cancer	0.000224	0.000259	CbGpPWpGaD
Bupranolol—ADRB1—Signaling by GPCR—PIK3CB—breast cancer	0.000223	0.000259	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—NRG1—breast cancer	0.000223	0.000258	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—PIK3CB—breast cancer	0.000222	0.000257	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—MTOR—breast cancer	0.000222	0.000257	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—H2AFX—breast cancer	0.000221	0.000256	CbGpPWpGaD
Bupranolol—ADRB2—GPCR downstream signaling—IL2—breast cancer	0.000221	0.000256	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—E2F1—breast cancer	0.000219	0.000254	CbGpPWpGaD
Bupranolol—ADRB2—Signaling by GPCR—PIK3CB—breast cancer	0.000218	0.000253	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—SPP1—breast cancer	0.000215	0.00025	CbGpPWpGaD
Bupranolol—ADRB1—Signaling by GPCR—CXCL8—breast cancer	0.000215	0.000249	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—CXCL8—breast cancer	0.000214	0.000247	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—ERBB3—breast cancer	0.000213	0.000247	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—FGFR2—breast cancer	0.000213	0.000247	CbGpPWpGaD
Bupranolol—ADRB3—Signaling by GPCR—HRAS—breast cancer	0.000212	0.000246	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—SPP1—breast cancer	0.000211	0.000244	CbGpPWpGaD
Bupranolol—ADRB2—Signaling by GPCR—CXCL8—breast cancer	0.00021	0.000243	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—CDKN1B—breast cancer	0.000209	0.000242	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—ERBB3—breast cancer	0.000208	0.000242	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—FGFR2—breast cancer	0.000208	0.000241	CbGpPWpGaD
Bupranolol—ADRB3—GPCR downstream signaling—AKT1—breast cancer	0.000206	0.000239	CbGpPWpGaD
Bupranolol—ADRB1—Signaling by GPCR—IL2—breast cancer	0.000205	0.000238	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—CASP3—breast cancer	0.000204	0.000237	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—TERT—breast cancer	0.000204	0.000237	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—IL2—breast cancer	0.000204	0.000236	CbGpPWpGaD
Bupranolol—ADRB3—Signaling by GPCR—IL6—breast cancer	0.000203	0.000235	CbGpPWpGaD
Bupranolol—ADRB2—Signaling by GPCR—IL2—breast cancer	0.000201	0.000232	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—TERT—breast cancer	0.0002	0.000232	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—CCND1—breast cancer	0.000199	0.000231	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—JUN—breast cancer	0.000199	0.00023	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—FGFR1—breast cancer	0.000198	0.00023	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—CTNNB1—breast cancer	0.000197	0.000228	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—HIF1A—breast cancer	0.000195	0.000226	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—FGFR1—breast cancer	0.000194	0.000225	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—MMP9—breast cancer	0.000193	0.000224	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—CDKN1A—breast cancer	0.000192	0.000223	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—PTEN—breast cancer	0.000192	0.000222	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—HIF1A—breast cancer	0.000191	0.000221	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—LEP—breast cancer	0.000191	0.000221	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—CAV1—breast cancer	0.000189	0.000219	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—MAPK8—breast cancer	0.000188	0.000218	CbGpPWpGaD
Bupranolol—ADRB3—Signaling by GPCR—AKT1—breast cancer	0.000187	0.000217	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—KDR—breast cancer	0.000187	0.000216	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—LEP—breast cancer	0.000187	0.000216	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—CAV1—breast cancer	0.000185	0.000214	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—KDR—breast cancer	0.000183	0.000212	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—ESR1—breast cancer	0.000182	0.000211	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—FN1—breast cancer	0.00018	0.000208	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—ESR1—breast cancer	0.000178	0.000206	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—SRC—breast cancer	0.000178	0.000206	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—NFKBIA—breast cancer	0.000178	0.000206	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—NOTCH1—breast cancer	0.000176	0.000204	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—FN1—breast cancer	0.000176	0.000204	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—NFKBIA—breast cancer	0.000174	0.000201	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—VEGFA—breast cancer	0.000173	0.000201	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—NOTCH1—breast cancer	0.000172	0.000199	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—KIT—breast cancer	0.000172	0.000199	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—APC—breast cancer	0.000172	0.000199	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—PIK3CG—breast cancer	0.000172	0.000199	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—STAT3—breast cancer	0.000172	0.000199	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—EGF—breast cancer	0.00017	0.000197	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—APC—breast cancer	0.000168	0.000195	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—PIK3CG—breast cancer	0.000168	0.000195	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—KIT—breast cancer	0.000168	0.000195	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—EGF—breast cancer	0.000166	0.000193	CbGpPWpGaD
Bupranolol—ADRB1—Signaling by GPCR—MAPK3—breast cancer	0.000165	0.000191	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—MAPK3—breast cancer	0.000164	0.00019	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—BRAF—breast cancer	0.000162	0.000187	CbGpPWpGaD
Bupranolol—ADRB2—Signaling by GPCR—MAPK3—breast cancer	0.000161	0.000187	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—MYC—breast cancer	0.00016	0.000185	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—TGFB1—breast cancer	0.000159	0.000184	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—BRAF—breast cancer	0.000158	0.000183	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—IGF1—breast cancer	0.000158	0.000183	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—AKT2—breast cancer	0.000157	0.000182	CbGpPWpGaD
Bupranolol—ADRB1—Signaling by GPCR—EGFR—breast cancer	0.000157	0.000182	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—EGFR—breast cancer	0.000156	0.000181	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—IGF1—breast cancer	0.000154	0.000179	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—AKT2—breast cancer	0.000154	0.000178	CbGpPWpGaD
Bupranolol—ADRB2—Signaling by GPCR—EGFR—breast cancer	0.000153	0.000178	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—PIK3CD—breast cancer	0.000151	0.000175	CbGpPWpGaD
Bupranolol—ADRB1—GPCR downstream signaling—PIK3CA—breast cancer	0.00015	0.000174	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—SERPINE1—breast cancer	0.00015	0.000173	CbGpPWpGaD
Bupranolol—ADRB1—Signaling by GPCR—KRAS—breast cancer	0.000148	0.000172	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—PIK3CD—breast cancer	0.000148	0.000172	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—KRAS—breast cancer	0.000147	0.000171	CbGpPWpGaD
Bupranolol—ADRB2—GPCR downstream signaling—PIK3CA—breast cancer	0.000147	0.00017	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—SERPINE1—breast cancer	0.000146	0.00017	CbGpPWpGaD
Bupranolol—ADRB2—Signaling by GPCR—KRAS—breast cancer	0.000145	0.000168	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—NOS3—breast cancer	0.000143	0.000166	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—NOS3—breast cancer	0.00014	0.000162	CbGpPWpGaD
Bupranolol—ADRB1—Signaling by GPCR—PIK3CA—breast cancer	0.000136	0.000158	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—MDM2—breast cancer	0.000136	0.000157	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—PIK3CA—breast cancer	0.000135	0.000157	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—RAF1—breast cancer	0.000135	0.000157	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—RELA—breast cancer	0.000134	0.000156	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—ERBB2—breast cancer	0.000134	0.000155	CbGpPWpGaD
Bupranolol—ADRB2—Signaling by GPCR—PIK3CA—breast cancer	0.000133	0.000154	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—MDM2—breast cancer	0.000133	0.000154	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—RAF1—breast cancer	0.000132	0.000153	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—MTOR—breast cancer	0.000132	0.000153	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—PIK3CB—breast cancer	0.000132	0.000153	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—RELA—breast cancer	0.000132	0.000152	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—TP53—breast cancer	0.000131	0.000152	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—ERBB2—breast cancer	0.000131	0.000151	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—MTOR—breast cancer	0.000129	0.000149	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—PIK3CB—breast cancer	0.000129	0.000149	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—CXCL8—breast cancer	0.000127	0.000147	CbGpPWpGaD
Bupranolol—ADRB1—Signaling by GPCR—HRAS—breast cancer	0.000126	0.000146	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—HRAS—breast cancer	0.000125	0.000145	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—CXCL8—breast cancer	0.000124	0.000144	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—CDKN1B—breast cancer	0.000124	0.000143	CbGpPWpGaD
Bupranolol—ADRB2—Signaling by GPCR—HRAS—breast cancer	0.000123	0.000143	CbGpPWpGaD
Bupranolol—ADRB1—GPCR downstream signaling—AKT1—breast cancer	0.000122	0.000142	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—CASP3—breast cancer	0.000121	0.000141	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—IL2—breast cancer	0.000121	0.00014	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—CDKN1B—breast cancer	0.000121	0.00014	CbGpPWpGaD
Bupranolol—ADRB1—Signaling by GPCR—IL6—breast cancer	0.000121	0.00014	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—IL6—breast cancer	0.00012	0.000139	CbGpPWpGaD
Bupranolol—ADRB2—GPCR downstream signaling—AKT1—breast cancer	0.00012	0.000139	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—CASP3—breast cancer	0.000119	0.000137	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—IL2—breast cancer	0.000118	0.000137	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—CCND1—breast cancer	0.000118	0.000137	CbGpPWpGaD
Bupranolol—ADRB2—Signaling by GPCR—IL6—breast cancer	0.000118	0.000137	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—JUN—breast cancer	0.000118	0.000137	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—CTNNB1—breast cancer	0.000117	0.000135	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—CCND1—breast cancer	0.000115	0.000134	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—JUN—breast cancer	0.000115	0.000134	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—MMP9—breast cancer	0.000115	0.000133	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—CTNNB1—breast cancer	0.000114	0.000133	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—CDKN1A—breast cancer	0.000114	0.000132	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—PTEN—breast cancer	0.000114	0.000132	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—MMP9—breast cancer	0.000112	0.00013	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—CDKN1A—breast cancer	0.000112	0.000129	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—MAPK8—breast cancer	0.000111	0.000129	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—PTEN—breast cancer	0.000111	0.000129	CbGpPWpGaD
Bupranolol—ADRB1—Signaling by GPCR—AKT1—breast cancer	0.000111	0.000129	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—AKT1—breast cancer	0.000111	0.000128	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—MAPK8—breast cancer	0.000109	0.000126	CbGpPWpGaD
Bupranolol—ADRB2—Signaling by GPCR—AKT1—breast cancer	0.000109	0.000126	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—SRC—breast cancer	0.000106	0.000122	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—SRC—breast cancer	0.000103	0.00012	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—VEGFA—breast cancer	0.000103	0.000119	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—STAT3—breast cancer	0.000102	0.000118	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—VEGFA—breast cancer	0.000101	0.000117	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—STAT3—breast cancer	9.97e-05	0.000116	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—MAPK3—breast cancer	9.74e-05	0.000113	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—MAPK3—breast cancer	9.53e-05	0.00011	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—MYC—breast cancer	9.47e-05	0.00011	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—TGFB1—breast cancer	9.45e-05	0.000109	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—MYC—breast cancer	9.26e-05	0.000107	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—EGFR—breast cancer	9.26e-05	0.000107	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—TGFB1—breast cancer	9.24e-05	0.000107	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—EGFR—breast cancer	9.06e-05	0.000105	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—KRAS—breast cancer	8.75e-05	0.000101	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—KRAS—breast cancer	8.56e-05	9.92e-05	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—PIK3CA—breast cancer	8.04e-05	9.32e-05	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—PIK3CA—breast cancer	7.86e-05	9.11e-05	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—TP53—breast cancer	7.78e-05	9.01e-05	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—TP53—breast cancer	7.61e-05	8.82e-05	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—HRAS—breast cancer	7.44e-05	8.62e-05	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—HRAS—breast cancer	7.28e-05	8.43e-05	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—IL6—breast cancer	7.12e-05	8.25e-05	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—IL6—breast cancer	6.96e-05	8.07e-05	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—AKT1—breast cancer	6.57e-05	7.61e-05	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—AKT1—breast cancer	6.42e-05	7.44e-05	CbGpPWpGaD
